Geron (GERN -5%) slips after posting a mixed Q1 report late yesterday that came up short on its...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN -5%) slips after posting a mixed Q1 report late yesterday that came up short on its bottom line. The company also announced plans to cut its workforce by about a third and discontinue its discovery research and companion diagnostics programs, as the pharmaceutical company plans to put its entire focus on the development of Imetelstat, a treatment for hematologic myeloid malignancies.